Risk factors, management, and outcomes of amniotic fluid embolism: A multicountry, population-based cohort and nested case-control study.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science, [2004]-

Embolism, Amniotic Fluid/*etiology ; Embolism, Amniotic Fluid/*therapy; Adult ; Australia/epidemiology ; Case-Control Studies ; Cohort Studies ; Female ; France/epidemiology ; Humans ; Incidence ; Logistic Models ; Maternal Mortality/trends ; Netherlands/epidemiology ; Odds Ratio ; Pregnancy ; Risk Factors ; Slovakia/epidemiology ; Surveys and Questionnaires ; Tranexamic Acid/therapeutic use ; Treatment Outcome ; United Kingdom/epidemiology

Background: Amniotic fluid embolism (AFE) remains one of the principal reported causes of direct maternal mortality in high-income countries. However, obtaining robust information about the condition is challenging because of its rarity and its difficulty to diagnose. This study aimed to pool data from multiple countries in order to describe risk factors, management, and outcomes of AFE and to explore the impact on the findings of considering United Kingdom, international, and United States AFE case definitions.
Methods and Findings: A population-based cohort and nested case-control study was conducted using the International Network of Obstetric Survey Systems (INOSS). Secondary data on women with AFE (n = 99-218, depending on case definition) collected prospectively in population-based studies conducted in Australia, France, the Netherlands, Slovakia, and the UK were pooled along with secondary data on a sample of control women (n = 4,938) collected in Australia and the UK. Risk factors for AFE were investigated by comparing the women with AFE in Australia and the UK with the control women identified in these countries using logistic regression. Factors associated with poor maternal outcomes (fatality and composite of fatality or permanent neurological injury) amongst women with AFE from each of the countries were investigated using logistic regression or Wilcoxon rank-sum test. The estimated incidence of AFE ranged from 0.8-1.8 per 100,000 maternities, and the proportion of women with AFE who died or had permanent neurological injury ranged from 30%-41%, depending on the case definition. However, applying different case definitions did not materially alter findings regarding risk factors for AFE and factors associated with poor maternal outcomes amongst women with AFE. Using the most liberal case definition (UK) and adjusting for the severity of presentation when appropriate, women who died were more likely than those who survived to present with cardiac arrest (89% versus 40%, adjusted odds ratio [aOR] 10.58, 95% confidence interval [CI] 3.93-28.48, p < 0.001) and less likely to have a source of concentrated fibrinogen (40% versus 56%, aOR 0.44, 95% CI 0.21-0.92, p = 0.029) or platelets given (24% versus 49%, aOR 0.23, 95% CI 0.10-0.52, p < 0.001). They also had a lower dose of tranexamic acid (median dose 0.7 g versus 2 g, p = 0.035) and were less likely to have had an obstetrician and/or anaesthetist present at the time of the AFE (61% versus 75%, aOR 0.38, 95% CI 0.16-0.90, p = 0.027). Limitations of the study include limited statistical power to examine factors associated with poor maternal outcome and the potential for residual confounding or confounding by indication.
Conclusions: The findings of our study suggest that when an AFE is suspected, initial supportive obstetric care is important, but having an obstetrician and/or anaesthetist present at the time of the AFE event and use of interventions to correct coagulopathy, including the administration of an adequate dose of tranexamic acid, may be important to improve maternal outcome. Future research should focus on early detection of the coagulation deficiencies seen in AFE alongside the role of tranexamic acid and other coagulopathy management strategies.
Competing Interests: The authors have declared that no competing interests exist.

Comment in: PLoS Med. 2019 Nov 12;16(11):e1002976. (PMID: 31714903)

J Matern Fetal Neonatal Med. 2018 Mar;31(5):661-665. (PMID: 28282766)
Obstet Gynecol. 2014 Mar;123(3):618-27. (PMID: 24499757)
Aust N Z J Obstet Gynaecol. 2013 Apr;53(2):152-7. (PMID: 23216366)
BMJ Open. 2017 Oct 5;7(10):e017713. (PMID: 28982832)
Lancet. 2017 May 27;389(10084):2105-2116. (PMID: 28456509)
BMC Pregnancy Childbirth. 2015 Dec 24;15:352. (PMID: 26703453)
BJOG. 2019 Feb;126(3):394-401. (PMID: 28755459)
Obstet Gynecol. 2012 Aug;120(2 Pt 1):318-24. (PMID: 22825091)
Am J Obstet Gynecol. 2008 Jul;199(1):49.e1-8. (PMID: 18295171)
Paediatr Perinat Epidemiol. 2013 Sep;27(5):436-41. (PMID: 23930779)
Obstet Gynecol. 2010 May;115(5):910-7. (PMID: 20410762)
PLoS One. 2012;7(12):e52893. (PMID: 23300807)
BJOG. 2005 Mar;112(3):263-5. (PMID: 15713136)
Am J Obstet Gynecol. 2016 Oct;215(4):408-12. (PMID: 27372270)
Am J Obstet Gynecol. 2009 Nov;201(5):445.e1-13. (PMID: 19879393)
J R Soc Med. 2000 Jul;93(7):346-50. (PMID: 10928020)
PLoS Med. 2014 Jul 08;11(7):e1001672. (PMID: 25003759)
Anesth Analg. 2018 Jan;126(1):175-182. (PMID: 28961562)
J Trauma. 2006 Jun;60(6 Suppl):S46-50. (PMID: 16763481)
BJOG. 2008 Mar;115(4):453-61. (PMID: 18201281)
Anesthesiology. 2011 Dec;115(6):1201-8. (PMID: 21720243)
Am J Obstet Gynecol. 2019 Mar;220(3):285-287. (PMID: 30481492)
BMC Pregnancy Childbirth. 2012 Feb 10;12:7. (PMID: 22325370)
Acta Obstet Gynecol Scand. 2014 Feb;93(2):127-31. (PMID: 24382256)
BJOG. 2007 Sep;114(9):1072-8. (PMID: 17617191)
BJOG. 2017 Jun;124(7):1097-1106. (PMID: 27581343)
Aust N Z J Obstet Gynaecol. 2012 Apr;52(2):195-203. (PMID: 22188386)
Obstet Gynecol. 2010 May;115(5):989-97. (PMID: 20410773)
Obstet Gynecol. 2008 Jan;111(1):97-105. (PMID: 18165397)
Br J Anaesth. 2014 Dec;113(6):922-34. (PMID: 24972790)
BJOG. 2016 Jan;123(1):100-9. (PMID: 25683758)
Transfusion. 2016 Dec;56(12):3042-3046. (PMID: 27805263)

NIHR-RP-011-032 United Kingdom DH_ Department of Health

6T84R30KC1 (Tranexamic Acid)

Date Created: 20191113 Date Completed: 20200207 Latest Revision: 20210110

20240105

PMC6850527

10.1371/journal.pmed.1002962

31714909